Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci: A comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia

Haematologica

Volumn 95, Issue 1, 2010, Pages 158-162

  Krieger, David ^a   Moericke, Anja ^b   Oschlies, Ilske ^c   Zimmermann, Martin ^a   Schrappe, Martin ^b   Reiter, Alfred ^a   Burkhardt, Birgit ^a,b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

ATM; CDKN2A B; LOH; Lymphoblastic leukemia; Lymphoblastic lymphoma; p53

Indexed keywords

ATM PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MICROSATELLITE DNA; PROTEIN P53;

ADOLESCENT; ARTICLE; CHILD; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME 9P; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE FREQUENCY; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; LYMPHATIC LEUKEMIA; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROGNOSIS; SCHOOL CHILD; T CELL LEUKEMIA; T CELL LYMPHOMA; TREATMENT RESPONSE;

ADOLESCENT; CELL CYCLE PROTEINS; CHILD; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; GENETIC LOCI; GENETIC MARKERS; HUMANS; LEUKEMIA, T-CELL; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN-SERINE-THREONINE KINASES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 73949121255     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.007526     Document Type: Article

References (22)

1. Raetz EA, Perkins SL, Bhojwani D, Smock K, Philip M, Carroll WL, et al. Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer. 2006;47(2): 130-40.
2. Uyttebroeck A, Vanhentenrijk V, Hagemeijer A, Boeckx N, Renard M, Wlodarska I, et al. Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma? Leuk Lymphoma. 2007;48(9):1745-54.
3. Burkhardt B, Moericke A, Klapper W, Greene F, Salzburg J, Damm-Welk C, et al. Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. Leuk Lymphoma. 2008;49(3):451-61.
4. Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol. 2008;8(5):380-90.
5. Graux C, Cools J, Michaux L, Vandenberghe P, Hagemeijer A. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia. 2006; 20(9):1496-510.
6. Kawamura M, Ohnishi H, Guo SX, Sheng XM, Minegishi M, Hanada R, et al. Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia. Leuk Res. 1999;23(2): 115-26.
7. Smock KJ, Nelson M, Tripp SR, Sanger WG, Abromowitch M, Cairo MS, et al. Characterization of childhood precursor Tlymphoblastic lymphoma by immunophenotyping and fluorescent in situ hybridization: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2008;51(4):489-94.
8. Reato G, Basso G, Putti MC, Cignetti A, Guarini A, Foa R. Microsatellite analysis in childhood acute lymphoblastic leukemia. Haematologica. 1998;83(5):403-7.
9. Stilgenbauer S, Liebisch P, James MR, Schroder M, Schlegelberger B, Fischer K, et al. Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders. Proc Natl Acad Sci USA. 1996;93(21):11837-41.
10. Takeuchi S, Koike M, Park S, Seriu T, Bartram CR, Taub HE, et al. The ATM gene and susceptibility to childhood T-cell acute lymphoblastic leukaemia. Br J Haematol. 1998; 103(2):536-8.
11. Burkhardt B, Woessmann W, Zimmermann M, Kontny U, Vormoor J, Doerffel W, et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous systemnegative stage III or IV lymphoblastic lymphoma. J Clin Oncol. 2006;24(3):491-9.
12. Moricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dordelmann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008; 111(9):4477-89.
13. Burkhardt B, Bruch J, Zimmermann M, Strauch K, Parwaresch R, Ludwig WD, et al. Loss of heterozygosity on chromosome 6q14-q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma. Leukemia. 2006; 20(8):1422-9.
14. Takeuchi S, Tsukasaki K, Bartram CR, Seriu T, Zimmermann M, Schrappe M, et al. Long-term study of the clinical significance of loss of heterozygosity in childhood acute lymphoblastic leukemia. Leukemia. 2003;17(1):149-54.
15. Rubnitz JE, Behm FG, Pui CH, Evans WE, Relling MV, Raimondi SC, et al. Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p16, MLL, and ETV6 gene abnormalities: results of St Jude Total Therapy Study XII. Leukemia. 1997; 11(8):1201-6.
16. Heyman M, Calero Moreno T, Liu Y, Grander D, Rasool O, Borgonova-Brandter L, et al. Inverse correlation between loss of heterozygosity of the short arm of chromosome 12 and p15ink4B/p16ink4 gene inactivation in childhood acute lymphoblastic leukaemia. Br J Haematol. 1997;98(1):147-50.
17. Okuda T, Shurtleff SA, Valentine MB, Raimondi SC, Head DR, Behm F, et al. Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood. 1995;85(9): 2321-30.
18. Zhou M, Gu L, Yeager AM, Findley HW. Incidence and clinical significance of CDKN2/MTS1/P16ink4A and MTS2/ P15ink4B gene deletions in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1997;14(2):141-50.
19. Kees UR, Burton PR, Lu C, Baker DL. Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. Blood. 1997;89(11):4161-6.
20. Moreno TC, Widell S, Czader M, Grander D, Soderhall S, Gustafsson G, et al. Inverse correlation between Ink4-locus deletions and ICM-DNA hyperdiploidy in childhood acute lymphoblastic leukaemia, relation to clinical characteristics and outcome. Eur J Haematol. 2000;65(6):390-8.
21. Ramakers-van Woerden NL, Pieters R, Slater RM, Loonen AH, Beverloo HB, van DE, et al. In vitro drug resistance and prognostic impact of p16INK4A/P15INK4B deletions in childhood T-cell acute lymphoblastic leukaemia. Br J Haematol. 2001; 112(3):680-90.
22. Heerema NA, Sather HN, Sensel MG, Liu-Mares W, Lange BJ, Bostrom BC, et al. Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood. 1999;94(5):1537-44.